Viviane Labrie

Viviane Labrie

Auto-generated profile, based on publicly available information

Viviane Labrie

Center for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, MI, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2011 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
MVMasoud Vedadi
Masoud Vedadi
DBDalia Barsyte-Lovejoy
Dalia Barsyte-Lovejoy
FLFeng Liu
Feng Liu
SRSYLVIE Rival-Gervier
SYLVIE Rival-Gervier
AAAbdellah Allali-Hassani
Abdellah Allali-Hassani
JJJian Jin
Jian Jin

1 January 2019 in Trends in Neurosciences
Verified
Journal Article
Open access
MJMichaela E. Johnson
Michaela E. Johnson
BSBenjamin Stecher
Benjamin Stecher
VLViviane Labrie
Viviane Labrie
LBLena Brundin
Lena Brundin
PBPatrik Brundin
Patrik Brundin
We hypothesize that Parkinson's disease (PD) pathogenesis can be divided into three temporal phases. During the first phase, 'triggers', such as viral infections or environmental toxins, spark the disease process in the brain and/or peripheral tissues. Triggers alone, however, may be insufficient, requiring 'facilitators' like peripheral inflammation for PD pathology to develop. Once the disease manifests, 'aggravators' spur further neurodegeneration and exacerbate symptoms. Aggravators are proposed to include impaired autophagy and cell-to-cell propagation of α-synuclein pathology. We believe clinical trials need to consider these three phases and target potential therapies at the appropriate stage of the disease process in order to be effective.

9 September 2012 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
TKTarang Khare
Tarang Khare
SPShraddha Pai
Shraddha Pai
KKKarolis Koncevicius
Karolis Koncevicius
MPMrinal Pal
Mrinal Pal
EKEdita Kriukiene
Edita Kriukiene
APArturas Petronis
Arturas Petronis
The 5-hydroxymethylcytosine (5-hmC) nucleoside is abundant in the brain for unknown reasons. Genome-wide analysis of the distribution of 5-hmC versus 5-methylcytosine (5-mC) in human and mouse tissues now shows that 5-hmC is enriched in genes with synaptic functions. The differential distribution of 5-hmC versus 5-mC at exon-intron boundaries in both human and mouse tissues further suggests a possible role for 5-hmC in pre-mRNA splicing. The 5-methylcytosine (5-mC) derivative 5-hydroxymethylcytosine (5-hmC) is abundant in the brain for unknown reasons. Here we characterize the genomic distribution of 5-hmC and 5-mC in human and mouse tissues. We assayed 5-hmC by using glucosylation coupled with restriction-enzyme digestion and microarray analysis. We detected 5-hmC enrichment in genes with synapse-related functions in both human and mouse brain. We also identified substantial tissue-specific differential distributions of these DNA modifications at the exon-intron boundary in human and mouse. This boundary change was mainly due to 5-hmC in the brain but due to 5-mC in non-neural contexts. This pattern was replicated in multiple independent data sets and with single-molecule sequencing. Moreover, in human frontal cortex, constitutive exons contained higher levels of 5-hmC relative to alternatively spliced exons. Our study suggests a new role for 5-hmC in RNA splicing and synaptic function in the brain.

31 October 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
BKBryan A. Killinger
Bryan A. Killinger
ZMZachary Madaj
Zachary Madaj
JSJacek W. Sikora
Jacek W. Sikora
NRNolwen Rey
Nolwen Rey
AHAlec J. Haas
Alec J. Haas
VLViviane Labrie
Viviane Labrie
The human appendix is a reservoir for α-synuclein aggregates and its removal may reduce the risk of Parkinson’s disease.

21 May 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
PLPeipei Li
Peipei Li
LMLee Marshall
Lee Marshall
GOGabriel Oh
Gabriel Oh
JJJennifer L. Jakubowski
Jennifer L. Jakubowski
DGDaniel Groot
Daniel Groot
VLViviane Labrie
Viviane Labrie
Epigenetic control of enhancers alters neuronal functions and may be involved in Alzheimer’s disease (AD). Here, we identify enhancers in neurons contributing to AD by comprehensive fine-mapping of DNA methylation at enhancers, genome-wide. We examine 1.2 million CpG and CpH sites in enhancers in prefrontal cortex neurons of individuals with no/mild, moderate, and severe AD pathology (n = 101). We identify 1224 differentially methylated enhancer regions; most of which are hypomethylated at CpH sites in AD neurons. CpH methylation losses occur in normal aging neurons, but are accelerated in AD. Integration of epigenetic and transcriptomic data demonstrates a pro-apoptotic reactivation of the cell cycle in post-mitotic AD neurons. Furthermore, AD neurons have a large cluster of significantly hypomethylated enhancers in the DSCAML1 gene that targets BACE1. Hypomethylation of these enhancers in AD is associated with an upregulation of BACE1 transcripts and an increase in amyloid plaques, neurofibrillary tangles, and cognitive decline.

11 July 2007 in Neuropsychopharmacology
Verified
Journal Article
Closed access
PDF file
SDSteven Duffy
Steven Duffy
VLViviane Labrie
Viviane Labrie
JRJohn C Roder
John C Roder